Basic Information
RNALocate ID: | RLID:11001708 |
RNA Symbol: | hsa-miR-122-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-122-5p |
RNA ID: | miRBase:MIMAT0000421 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23663360 |
Tissue/Cell Line: | Plasma |
Method: | Next-generation RNA sequencing |
Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001744 | Cytoplasm | Huh-7 cells|Sorafenib-resistant Huh-7 cells (Huh-7-DR) | 29253196 |
RLID:01001745 | Cytoplasm | Huh-7 cells | 29486652 |
RLID:01001746 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001747 | Endoplasmic reticulum | Huh-7 cells | 26304123 |
RLID:01001748 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001749 | Nucleus | Adjacent noncancerous tissue|HCC tissue|Huh-7 cells|Sorafenib-resistant Huh-7 cells (Huh-7-DR) | 29253196 |
RLID:01001750 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001751 | Polysome | Human cervical cancer cell line (HeLa) | 25609084 |
RLID:11001705 | Exosome | Breast cancer cell lines (MCF10A|MDA-MB-231) | 25621950 |
RLID:11001706 | Exosome | B cell line (Raji) | 21505438 |
RLID:11001707 | Exosome | Brain tissue | 23382797 |
RLID:11001709 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11001710 | Exosome | B cell lymphoma cell lines|EBV-transformed lymphoblastoid B cells | 25242326 |
RLID:11001711 | Microvesicle | Plasma | 23077538 |
RLID:11001712 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000074 | Exosome | Blood|Chronic lymphocytic leukemia cells | |
RLID-D:11000349 | Microvesicle | Blood|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-122-5p | Disease of metabolism | MNDR-E-MI-05314 |
MNDR | hsa-miR-122-5p | Oral squamous cell carcinoma | MNDR-E-MI-05315 |
MNDR | hsa-miR-122-5p | Lymphoma | MNDR-E-MI-05316 |
MNDR | hsa-miR-122-5p | Cutaneous t cell lymphoma | MNDR-E-MI-05317 |
MNDR | hsa-miR-122-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-05318 |
MNDR | hsa-miR-122-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-05319 |
MNDR | hsa-miR-122-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-05320 |
MNDR | hsa-miR-122-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-05321 |
MNDR | hsa-miR-122-5p | Her2-receptor positive breast cancer | MNDR-E-MI-05322 |
MNDR | hsa-miR-122-5p | Breast cancer luminal a | MNDR-E-MI-05323 |
MNDR | hsa-miR-122-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-05324 |
MNDR | hsa-miR-122-5p | Prostate cancer | MNDR-E-MI-05325 |
MNDR | hsa-miR-122-5p | Gastric cancer | MNDR-E-MI-05326 |
MNDR | hsa-miR-122-5p | Alzheimer disease | MNDR-E-MI-05327 |
MNDR | hsa-miR-122-5p | Head and neck cancer | MNDR-E-MI-05328 |
MNDR | hsa-miR-122-5p | Primary biliary cirrhosis | MNDR-E-MI-05329 |
MNDR | hsa-miR-122-5p | Huntington disease | MNDR-E-MI-05330 |
MNDR | hsa-miR-122-5p | Cardiovascular disease | MNDR-E-MI-05331 |
MNDR | hsa-miR-122-5p | Moyamoya disease | MNDR-E-MI-05332 |
MNDR | hsa-miR-122-5p | Biliary atresia | MNDR-E-MI-05333 |
MNDR | hsa-miR-122-5p | Parkinson disease | MNDR-E-MI-05334 |
MNDR | hsa-miR-122-5p | Basal-like breast cancer | MNDR-E-MI-05335 |
MNDR | hsa-miR-122-5p | Pituitary neoplasms | MNDR-E-MI-05336 |
MNDR | hsa-miR-122-5p | Pancreatic cancer | MNDR-E-MI-05337 |
MNDR | hsa-miR-122-5p | HCV | MNDR-E-MI-05338 |
MNDR | hsa-miR-122-5p | Melanoma | MNDR-E-MI-05339 |
MNDR | hsa-miR-122-5p | Hepatitis B | MNDR-E-MI-05340 |
MNDR | hsa-miR-122-5p | Colon cancer | MNDR-E-MI-05341 |
MNDR | hsa-miR-122-5p | Ischemic attack transient | MNDR-E-MI-05342 |
MNDR | hsa-miR-122-5p | Familial ovarian cancer | MNDR-E-MI-05343 |
MNDR | hsa-miR-122-5p | Kidney cancer | MNDR-E-MI-05344 |
MNDR | hsa-miR-122-5p | Glioblastoma | MNDR-E-MI-05345 |
MNDR | hsa-miR-122-5p | Glioma | MNDR-E-MI-05346 |
MNDR | hsa-miR-122-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-05347 |
MNDR | hsa-miR-122-5p | Gastrointestinal cancer | MNDR-E-MI-05348 |
MNDR | hsa-miR-122-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-05349 |
MNDR | hsa-miR-122-5p | Osteosarcoma | MNDR-E-MI-05350 |
MNDR | hsa-miR-122-5p | Coronary artery disease | MNDR-E-MI-05351 |
MNDR | hsa-miR-122-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-05352 |
MNDR | hsa-miR-122-5p | Liver cancer | MNDR-E-MI-05353 |
MNDR | hsa-miR-122-5p | Uterine cancer | MNDR-E-MI-05354 |
MNDR | hsa-miR-122-5p | Cervical squamous cell carcinoma | MNDR-E-MI-05355 |
MNDR | hsa-miR-122-5p | Pituitary adenoma | MNDR-E-MI-05356 |
MNDR | hsa-miR-122-5p | Lung squamous cell carcinoma | MNDR-E-MI-05357 |
MNDR | hsa-miR-122-5p | Carcinoma lung non-small-cell | MNDR-E-MI-05358 |
MNDR | hsa-miR-122-5p | Lung adenocarcinoma | MNDR-E-MI-05359 |
MNDR | hsa-miR-122-5p | Pancreatic adenocarcinoma | MNDR-E-MI-05360 |
MNDR | hsa-miR-122-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-05361 |
MNDR | hsa-miR-122-5p | Kidney renal clear cell carcinoma | MNDR-E-MI-05362 |
MNDR | hsa-miR-122-5p | Clear cell renal cell carcinoma | MNDR-E-MI-05363 |
MNDR | hsa-miR-122-5p | Biliary tract cancer | MNDR-E-MI-05364 |
MNDR | hsa-miR-122-5p | Neoplasms of the small intestine | MNDR-E-MI-05365 |
MNDR | hsa-miR-122-5p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-05366 |
MNDR | hsa-miR-122-5p | Cholangiocarcinoma | MNDR-E-MI-05367 |
MNDR | hsa-miR-122-5p | Esophageal cancer | MNDR-E-MI-05368 |
MNDR | hsa-miR-122-5p | Liver cirrhosis | MNDR-E-MI-05369 |
MNDR | hsa-miR-122-5p | Synovial sarcoma | MNDR-E-MI-05370 |
MNDR | hsa-miR-122-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-05371 |
MNDR | hsa-miR-122-5p | Early hepatocellular carcinoma | MNDR-E-MI-05372 |
MNDR | hsa-miR-122-5p | Familiar ovarian carcinoma | MNDR-E-MI-05373 |
MNDR | hsa-miR-122-5p | B-cell lymphoma | MNDR-E-MI-05374 |
MNDR | hsa-miR-122-5p | Rheumatoid arthritis | MNDR-E-MI-05375 |
MNDR | hsa-miR-122-5p | Malignant pleural mesothelioma | MNDR-E-MI-05376 |
MNDR | hsa-miR-122-5p | Retinoblastoma | MNDR-E-MI-05377 |
MNDR | hsa-miR-122-5p | Osteoarthritis | MNDR-E-MI-05378 |
MNDR | hsa-miR-122-5p | Knee osteoarthritis | MNDR-E-MI-05379 |
MNDR | hsa-miR-122-5p | Psoriasis | MNDR-E-MI-05380 |
MNDR | hsa-miR-122-5p | Colorectal cancer | MNDR-E-MI-05381 |
MNDR | hsa-miR-122-5p | Nasopharynx carcinoma | MNDR-E-MI-05382 |
MNDR | hsa-miR-122-5p | Type 2 diabetes mellitus | MNDR-E-MI-05383 |
MNDR | hsa-miR-122-5p | Acute myocardial infarction | MNDR-E-MI-05384 |
MNDR | hsa-miR-122-5p | Fatty liver disease | MNDR-E-MI-05385 |
MNDR | hsa-miR-122-5p | Multiple myeloma | MNDR-E-MI-05386 |
MNDR | hsa-miR-122-5p | Acute lymphocytic leukemia | MNDR-E-MI-05387 |
MNDR | hsa-miR-122-5p | Infection | MNDR-E-MI-05388 |
MNDR | hsa-miR-122-5p | Nasopharyngeal cancer | MNDR-E-MI-05389 |
MNDR | hsa-miR-122-5p | Aids dementia complex | MNDR-E-MI-05390 |
MNDR | hsa-miR-122-5p | Liver failure | MNDR-E-MI-05391 |
MNDR | hsa-miR-122-5p | Acute liver failure | MNDR-E-MI-05392 |
MNDR | hsa-miR-122-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-05393 |
MNDR | hsa-miR-122-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-05394 |
MNDR | hsa-miR-122-5p | Stroke lacunar | MNDR-E-MI-05395 |
MNDR | hsa-miR-122-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-05396 |
MNDR | hsa-miR-122-5p | Breast cancer her3+ negative | MNDR-E-MI-05397 |
MNDR | hsa-miR-122-5p | High grade dysplastic nodule | MNDR-E-MI-05398 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | AACS | Homo sapiens | RR00020644 |
TOP